Langlara Injection, Solution
Product Images NDC 87682-090

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Langlara (NDC 87682-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lanexa Biologics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Langlara 1)

A line graph comparing glucose infusion rates over time after subcutaneous injection for insulin glargine and NPH insulin. The x-axis represents time in hours up to 30 hours, and the y-axis represents glucose infusion rate in mg/kg/min. The graph shows data for 20 subjects per treatment, with an annotated end of observation period.*

FDA Label Image

Figure10 (Langlara 10)

Illustration showing a person holding a prefilled syringe of LANGLARA injection, solution, 100 units/mL insulin glargine-aldy. The person is wiping the syringe's needle cap with an alcohol swab, demonstrating proper preparation for subcutaneous injection.*

FDA Label Image

Figure11 (Langlara 11)

An instructional illustration showing two hands holding and preparing to snap or twist off a small plastic cap or component, likely related to the administration or preparation of an injection. No text or further details are visible.*

FDA Label Image

Figure12 (Langlara 12)

An instruction illustration showing how to properly remove the cap from a LANGLARA injection pen by twisting it off with one hand. It includes a prohibition symbol over an incorrect method of pulling the cap straight off with fingers.*

FDA Label Image

Figure13 (Langlara 13)

An instructional illustration depicting the preparation of an injection pen device filled with Langlara (insulin glargine-aldy) 100 IU/mL solution. The image shows hands holding the pen and screwing on or attaching a needle cap, likely demonstrating how to ready the device for subcutaneous administration.*

FDA Label Image

Figure14 (Langlara 14)

An instructional illustration showing a hand holding a syringe with a blue safety cap and a needle, and another hand dropping the used needle into a container labeled 'SHARPS.' This image demonstrates safe needle disposal after injection.*

FDA Label Image

Figure15 (Langlara 15)

An instructional diagram showing hands holding a Langlara insulin glargine-aldy 100 IU/mL injection pen. The illustration highlights dialing the dose by turning the dose selector, with a close-up view of the dose window indicating the number "2." The blue arrows demonstrate the direction to turn the dial for dose adjustment.*

FDA Label Image

Figure16 (Langlara 16)

An instructional illustration showing hands holding a prefilled injection pen with liquid being expelled from the needle tip. A close-up highlights the needle with a drop of liquid emerging, demonstrating proper priming or air removal before injecting.*

FDA Label Image

Figure17 (Langlara 17)

The image shows a Langlara insulin glargine-aldy injection pen, labeled for subcutaneous use with a concentration of 100 units/mL. The pen features a gray needle cap at the front, a dosage window displaying a numeric setting, and a blue and white label with the Langlara brand name, drug description, and strength. The labeler is Lanexa Biologics, LLC.*

FDA Label Image

Figure18 (Langlara 18)

An instructional illustration showing how to remove the cap from a Langlara insulin glargine-aldy injection pen. The image depicts two hands gripping the pen and lifting the cap off with an upward arrow indicating the removal direction.*

FDA Label Image

Figure19 (Langlara 19)

An illustration showing a close-up view of a dosage selector dial on an injection pen. The dial is set to 20 units, as indicated by the marked number and the text '20 units selected' next to it.*

FDA Label Image

Figure2 (Langlara 2)

Alcohol pad single-use packets labeled with 'Alcohol Pad 75% Alcohol For Disinfection Use.' The image shows individual sealed packets, typically used for cleaning the skin before injection.*

FDA Label Image

Figure20 (Langlara 20)

An illustration shows a partial calendar page indicating the year 2022, accompanied by text stating "21 units selected." This likely relates to dosage selection but contains no branding or product-specific information.*

FDA Label Image

Figure21 (Langlara 21)

An instructional illustration showing a hand holding a Langlara prefilled injection pen. The image depicts the pen being pressed against a surface with the needle extended and an arrow indicating the injection direction.*

FDA Label Image

Figure22 (Langlara 22)

An instructional diagram showing a hand holding a LANGLARA insulin glargine-aldy injection pen. It illustrates proper technique to remove the pen cap by pulling it straight off, with a close-up highlighting the correct position of the thumb. A red circle indicates an incorrect removal method with the thumb improperly positioned.*

FDA Label Image

Figure23 (Langlara 23)

An instructional illustration showing a hand holding a syringe with the needle inserted into the skin. The image highlights a 10-second wait time, indicated by a clock icon, suggesting that the syringe should remain in place for 10 seconds after injection.*

FDA Label Image

Figure24 (Langlara 24)

An instructional illustration showing two hands holding a syringe. The left hand holds the syringe body with the needle exposed, while the right hand holds a protective needle cap being removed as indicated by a right-pointing arrow. The image demonstrates proper removal of the needle cap before injection.*

FDA Label Image

Figure25 (Langlara 25)

An instructional diagram showing how to twist and remove the cap from a Langlara insulin glargine-aldy injection pen. The illustration features hands gripping the pen and twisting the cap to remove it, with directional arrows indicating the motion required.*

FDA Label Image

Figure26 (Langlara 26)

An instructional illustration showing two hands disposing of a used needle cap into a container labeled 'SHARPS.' The left hand is holding the container, while the right hand is dropping the needle cap inside, emphasizing safe disposal of needles.*

FDA Label Image

Figure27 (Langlara 27)

An instructional illustration showing hands holding a Langlara insulin glargine-aldy injection pen. One hand is pulling the cap off the pen, indicated by a left-pointing arrow. The pen displays a dosage window and a label with the product name and strength.*

FDA Label Image

Figure28 (Langlara 28)

Box label for Langlara (insulin glargine-aldy) injection 100 units/mL (U-100), a subcutaneous injection. The label indicates it is for single-patient use only and lists inactive ingredients. Manufactured by Sunshine Lake Pharma in China and distributed by Lanexa Biologics, LLC, Trevose, PA. The packaging includes storage, dosage, and usage warnings, with space to record initial use dates for up to five pens.*

FDA Label Image

Figure3 (Langlara 3)

An illustration of a container labeled 'SHARPS' intended for the safe disposal of sharp medical instruments such as needles. The container is shown with a closed lid and a simple design suitable for medical or home use.*

FDA Label Image

Figure4 (Langlara 4)

An anatomical illustration showing preferred injection sites for subcutaneous administration. The highlighted areas include the upper arms, stomach, and thighs on a human body figure, labeled accordingly.*

FDA Label Image

Figure5 (Langlara 5)

An instructional diagram showing components of the Langlara insulin glargine-aldy injection pen, 100 IU/mL. It details the pen cap, needle assembly (not included), and pen body with parts labeled such as insulin reservoir, rubber seal, plunger, insulin scale, dose window, dose selector, and injection button.*

FDA Label Image

Figure6 (Langlara 6)

The image shows a Langlara insulin glargine-aldy injection pen labeled for single patient use only. The visible strength is 100 units per milliliter (U-100). The pen is white with a blue and orange label, including dosage and administration details, and has a dose selection dial and a blue cap. The labeler is Lanexa Biologics, LLC.*

FDA Label Image

Figure7 (Langlara 7)

LANGLARA injection, solution 100 IU/mL vial label. The label shows a blue and white vial with a QR code and space for lot and expiration date information. The labeler is Lanexa Biologics, LLC.*

FDA Label Image

Figure8 (Langlara 8)

An instructional illustration showing hands holding and operating a Langlara injection pen. The image includes a close-up of pressing the injection button with an arrow indicating the direction of the press to deliver the insulin glargine-aldy subcutaneous injection.*

FDA Label Image

Figure9 (Langlara 9)

Label of LANGLARA insulin glargine-aldy injection, solution, 100 units/mL (U-100) for subcutaneous use. The label indicates it is for single patient use only and is marketed by Lanexa Biologics, LLC. The image includes a partial view of an insulin pen showing dosage markings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.